Approximately half of oncologists discuss genomic testing with their patients, and several practice-level factors influence oncologists’ likelihood of discussing the associated costs, a study in the Journal of the National Cancer Institute reports.
Researchers evaluated the frequency of race reporting and race representation in pivotal drug trials that are used to establish standards of care in oncology treatment.
The FDA is warning consumers to stop using products known as Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, and Water Purification Solution due to numerous reports of significant health issues.
Mvasi is a biosimilar to Avastin; Kanjinti is a biosimilar to Herceptin.
The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
No reports of adverse events have been received at this time, as per the Company.
The FDA has approved Zirabev (bevacizumab-bvzr; Pfizer), a biosimilar to Avastin (bevacizumab; Genentech).
The number of cancer survivors is projected to increase to more than 22.1 million by Jan. 1, 2030, based on growth and aging of the population alone.
Kognito, a health simulation company, is applying its simulation technology to patient education, to address a gap in patient knowledge.
